Highest-materiality recent filing
LianBio to wind down operations, delist from Nasdaq, pay $4.80 special dividend
Board approves wind-down; workforce reduction of ~50% (over 50 employees) in Q1 2024.
LianBio sells NBTXR3 rights in Asia to Janssen for $25M upfront plus potential $5M milestone
Asset Purchase Agreement with Janssen (Johnson & Johnson) executed Dec 22, 2023.
LianBio CFO Yi Larson resigns; Ehong Gu named interim CFO
Yi Larson resigned as CFO effective December 19, 2023, to pursue other opportunities.
CEO Yizhe Wang resigned effective Dec 16, 2023; receives severance of $1,525,000 plus accelerated vesting.
LianBio Board Unanimously Rejects $4.30/Share Unsolicited Bid from Concentra Biosciences
Board unanimously determined not to pursue unsolicited proposal from Concentra Biosciences.
LianBio confirms unsolicited $4.30/share buyout proposal from Concentra plus CVR
Proposal: $4.30 per share cash plus a contingent value right for 80% of net proceeds from licensing or disposition of LianBio's programs.
LianBio Q3 net loss $24M, inks $350M BMS mavacamten deal, strategic review ongoing
Net loss of $24.0M in Q3 2023 vs $21.9M loss in Q3 2022; cash $252.2M as of Sep 30, 2023.
LianBio terminates mavacamten license for $350M; TP-03 Phase 3 shows mixed results
Terminated mavacamten license with BMS/MyoKardia; receives $350M payment and released from $127.5M in milestones.
Net loss $21.6M in Q2 2023 vs $42.4M in Q2 2022; R&D expenses fell to $9.5M from $28.6M.
LianBio shareholders elect three Class II directors, ratify KPMG as auditor
Susan Silbermann, Adam Stone, Wei Wei Chen elected as Class II directors with >95% votes in favor.
LianBio Q1 net loss $24M; mavacamten NDA accepted in China with priority review
Net loss of $24.0M in Q1 2023 vs $27.7M in Q1 2022; cash $286.6M at March 31, 2023.
LianBio presents EXPLORER-CN topline data and mavacamten China opportunity at virtual event
Virtual investor event held May 1, 2023 to discuss EXPLORER-CN topline data for mavacamten.
EXPLORER-CN met primary endpoint: Valsalva LVOT gradient improvement from baseline to week 30 vs placebo (p<0.001).
China NMPA accepts with priority review LianBio's NDA for mavacamten in oHCM
NMPA accepted NDA for mavacamten for symptomatic obstructive HCM in adults; priority review granted.
LianBio reports FY2022 net loss of $110.3M; cash $302.4M with runway through end of 2024
Net loss $18.3M in Q4 2022 ($21.2M in Q4 2021); FY2022 loss $110.3M vs $196.3M in 2021.
CFO Yi Larson gets new 3-year employment contract with $510K base salary
Initial term from Oct 1, 2022 to Sep 30, 2025, with auto-renewal for one-year periods.
$20M upfront payment from previously restricted cash paid by Pfizer in 2020 under the existing strategic collaboration.
LianBio President and Chief Strategy Officer Debra Yu resigns effective Jan 1, 2023
Debra Yu, President and CSO, resigns effective Jan 1, 2023 to pursue other business opportunities.
LianBio Q3 net loss $21.9M; cash $331.8M; mavacamten Phase 3 data expected mid-2023
Net loss of $21.9M for Q3 2022 vs $13.1M YoY; R&D expenses $8.3M, G&A $16.3M.
LianBio halts infigratinib CCA program after Helsinn exits US market
Helsinn Healthcare SA permanently discontinues Truseltiq (infigratinib) in US; plans to withdraw NDA for business reasons.
LianBio Q2 net loss $42.4M; cash $349.4M; mavacamten China Phase 3 enrollment complete
Net loss of $42.4M in Q2 2022 vs. $100.4M loss in Q2 2021; R&D expenses fell to $28.6M.
LianBio shareholders elect two Class I directors, ratify KPMG as auditor
Tassos Gianakakos received 89,412,158 votes for; 502,057 against; 3,399,403 abstained.
LianBio Q1 net loss narrows to $27.7M; cash $389.1M; mavacamten FDA approval
Net loss of $27.7M vs $61.6M in Q1 2021; R&D expenses fell to $12.3M from $53.4M.
LianBio appoints Wei Wei Chen as independent director and Audit Committee member
Wei Wei Chen appointed to LianBio Board as Class II director effective April 6, 2022; term ends at 2023 annual shareholder meeting.
LianBio reports Q4 net loss $21.2M; cash $403.2M; mavacamten Phase 3 ongoing
Net loss $21.2M in Q4 2021 vs $12.7M Q4 2020; full-year loss $196.3M vs $139.6M.
Corporate presentation posted to company website on March 2, 2022.
LianBio Q3 net loss narrows to $13.1M; completed $334.5M IPO
Net loss of $13.1M ($0.63 per share) narrowed from $120.2M ($11.71) in Q3 2020.
LianBio subsidiary signs lease for Shanghai HQ; total base rent ~$4.9M through March 2025
Lease for 2,313.46 sq m office space at Corporate Avenue, Shanghai; initial term Nov 16, 2021 to Mar 31, 2025.
LianBio files amended charter authorizing 2.9B ordinary shares upon IPO closing
Authorized 2,923,900,005 ordinary shares via amended memorandum and articles of association.
In connection with Ms. Larson’s departure, effective December 19, 2023, the Board appointed Ehong Gu as Interim Chief Financial Officer of the Company, in which role she will act as the Company’s principal financial officer and principal accounting officer.
Yi Larson, the Company’s Chief Financial Officer, has decided to resign from the Company, effective December 19, 2023, to pursue other business and professional interests and opportunities.
Yizhe Wang, the Company’s Chief Executive Officer and member of the Company’s board of directors (the “Board”), has decided to resign as Chief Executive Officer and as a member of the Board, effective December 16, 2023, to pursue other business and professional interests and opportunities.
Debra Yu, the Company’s President and Chief Strategy Officer, has decided to resign from the Company, effective January 1, 2023
On April 6, 2022, the Board of Directors (the “Board”) of LianBio (the “Company”) appointed Wei Wei Chen as an independent director, effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material